432

Baseline Features of Participants With Idiopathic Hypersomnia: Insights From the DUET Study

DUET STUDY 407

David T. Plante, MD, PhD[1]; Deborah A. Nichols, MS[2]; Teresa L. Steininger, PhD[2]; Jessica K. Alexander, PhD[2]; Douglas S. Fuller, MS[3]; Chad Ruoff, MD[4]

[1]Department of Psychiatry, University of Wisconsin–Madison, Madison, WI, USA; [2]Jazz Pharmaceuticals, Palo Alto, CA, USA; [3]Jazz Pharmaceuticals, Philadelphia, PA, USA; [4]Mayo Clinic, Scottsdale, AZ, USA

Introduction

- Low-sodium oxybate (LXB, Xywav®) is approved by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults and the treatment of excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy[1-4]
- Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, open-label interventional study (NCT05875974)
- This patient-centric study assesses the association of LXB treatment with changes in sleep architecture (polysomnography [PSG]), nighttime/daytime symptoms, and functional outcomes in adults diagnosed with idiopathic hypersomnia or narcolepsy (type 1 or type 2)
- The DUET study is actively recruiting participants in the United States and Canada; reported here are baseline features of the participants with idiopathic hypersomnia enrolled thus far
  - For further insights into the DUET study, including patient-centric and novel design elements and other cohort findings, please refer to Abstract 1106/Poster 304, Abstract 655/Poster 283, and Abstract 1337/Poster 437, respectively

Objective

- The primary objective of DUET is to evaluate the change in EDS in participants with idiopathic hypersomnia or narcolepsy treated with LXB

Methods

Figure 1. Study Design



EoT, end-of-treatment period; LXB, low-sodium oxybate; PK, pharmacokinetics; PSG, polysomnography; SDP, stable-dose period; V, visit.

Table 1. Key Inclusion and Exclusion Criteria

Key Inclusion Criteria

1. 18–75 years of age (inclusive) at time of signing informed consent form
2. Primary diagnosis of idiopathic hypersomnia (*International Classification of Sleep Disorders – Third Edition* [ICSD-3] criteria) or narcolepsy type 1 or type 2 (ICSD-3 or *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* criteria)
3. If not currently taking an oxybate medication, has clinically significant symptoms of excessive daytime sleepiness, with Epworth Sleepiness Scale (ESS) score >10 at screening visit 1; if currently taking an oxybate medication, has ESS score >10 at baseline visit 2 (after washout period)
4. If currently taking an anticataplectic or an alerting agent, has been taking same dosage for ≥1 month before screening visit 1 and is not planning to adjust dosage during study period

Key Exclusion Criteria

1. Evidence of a previous untreated or inadequately treated sleep disorder considered by investigator to negatively impact study conduct. Disorders include sleep-disordered breathing, parasomnias, circadian rhythm sleep disorders, and restless legs syndrome and are determined by a previous sleep-laboratory diagnosis or interview using Diagnostic Interview for Sleep Patterns and Disorders modules
2. Evidence of untreated or inadequately treated sleep-disordered breathing, defined by apnea-hypopnea index >10,[a] during baseline visit 2
3. History or presence of an unstable or clinically significant medical condition (eg, chronic pain condition that may impact sleep), behavioral or psychiatric disorder (including active suicidal ideation or current or past [within 1 year] major depressive episode), or history or presence of another neurologic disorder or surgical history that might affect participant's safety or interfere with study conduct, based on investigator's judgment
4. Took within 1 month before screening, is taking, or plans to take any of the following:
   a. Substance or medication contraindicated with low-sodium oxybate (LXB) use (specifically, alcohol or a sedative hypnotic)
   b. Medication with known drug–drug interaction with LXB
   c. Medication that may have electroencephalography effects similar to those of LXB
   d. Medication known to have clinically significant central nervous system sedative effects
   e. Another medication, natural health product, or substance from which participant experiences clinically significant sedation, based on investigator's clinical judgment

[a]According to the rules of the US Centers for Medicare & Medicaid Services.

- The primary endpoint of the DUET study is change in Epworth Sleepiness Scale[5] (ESS) total score from baseline to end of treatment
- Secondary efficacy endpoints for the idiopathic hypersomnia cohort include change in Idiopathic Hypersomnia Severity Scale score, Patient Global Impression of Severity, and Patient Global Impression of Change from baseline to end of treatment
- Baseline data for the first 24 participants with idiopathic hypersomnia who provided informed consent, passed screening, and have taken ≥1 dose of LXB as of February 5, 2024 are presented here (anticipated n=50 dosed participants)

Results

Figure 2. Baseline Demographics for First 24 Dosed Participants With Idiopathic Hypersomnia

Age, years
Mean (SD): 40.5 (13.4) Median (min, max): 38.5 (20, 75)

Body mass index, kg/m²
Mean (SD): 28.3 (6.4) Median (min, max): 28.2 (19.3, 41.4)



Participant of childbearing potential, n (%)[a]
Yes: 12 (50.0)

[a]Out of N=24 participants.
max, maximum; min, minimum; SD, standard deviation.

- Baseline demographics for the first 24 dosed DUET participants with idiopathic hypersomnia are similar to those reported in other studies of idiopathic hypersomnia[6-9]
  - Most participants are female (75.0%, n=18) and White (83.3%, n=20)

Table 3. Key Concomitant Alerting Medications at Study Entry for First 24 Dosed Participants With Idiopathic Hypersomnia

ATC Level 4 Term and Preferred Terms, n (%)	n=24
Centrally acting sympathomimetics	11 (45.8)
Amphetamine aspartate, amphetamine sulfate, dexamphetamine saccharate, dexamphetamine sulfate	5 (20.8)
Solriamfetol hydrochloride	3 (12.5)
Modafinil	2 (8.3)
Armodafinil	1 (4.2)
Methylphenidate	1 (4.2)
Other antidepressants	3 (12.5)
Bupropion hydrochloride	1 (4.2)
Other nervous system drugs	1 (4.2)
Pitolisant hydrochloride	1 (4.2)

ATC, Anatomical Therapeutic Chemical.

- At study entry, some participants were taking alerting agents, most commonly amphetamines (20.8%)

Table 2. Oxybate Use Before Study Entry for First 24 Dosed Participants With Idiopathic Hypersomnia

Oxybate Type at Screening, n (%)	n=24
Not currently taking oxybate	17 (70.8)
Currently taking oxybate	7 (29.2)
Low-sodium oxybate	7 (29.2)
Sodium oxybate	0

- Of the 24 participants enrolled thus far and reported in this poster, 7 participants were taking oxybate at screening, while 17 were not currently taking oxybate

Figure 3. Symptom Analysis for First 24 Dosed Participants With Idiopathic Hypersomnia

Average Time From Symptom Onset to Diagnosis



N=24

- Participants reported a long delay between when their symptoms first started and when they received a diagnosis of idiopathic hypersomnia—a mean (SD) of 9.1 (8.5) years, or a median (minimum, maximum) of 5.0 (0, 33.0) years

Current Symptoms at Study Entry



- The most common symptoms reported at study entry were EDS (95.8%), fatigue (75.0%), and brain fog/cognitive dysfunction (66.7%)
  - Half of the participants reported experiencing sleep inertia

Conclusions

- Demographic features of the participants with idiopathic hypersomnia enrolled in DUET, reported here, are similar to those reported in a pivotal clinical study and in a real-world study of idiopathic hypersomnia[6-9]
  - These initial results are limited in that they include, as of February 5, 2024, only the first 24 dosed participants with idiopathic hypersomnia
- Once completed, the DUET study is expected to enhance our understanding of idiopathic hypersomnia and the treatment effects of LXB

References: 1. Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc. **2.** Szarfman A, et al. *N Engl J Med.* 1995;333(19):1291. **3.** US Food and Drug Administration. Clinical review for Binosto, NDA 202344. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202344Orig1s000MedR.pdf. Accessed February 28, 2023. **4.** US Food and Drug Administration. Quantitative labeling of sodium, potassium, and phosphorus for human over-the-counter and prescription drug products. Guidance for industry. 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug. Accessed October 11, 2022. **5.** Johns MW. *Sleep.* 1991;14(6):540-545. **6.** Dauvilliers Y, et al. *Lancet Neurol.* 2022;21(1):53-65. **7.** Thorpy MJ, et al. *Nat Sci Sleep.* 2022;14:1901-1917. **8.** Schneider LD, et al. *Nat Sci Sleep.* 2023;15:89-101. **9.** Stevens J, et al. *Nat Sci Sleep.* 2023;15:593-606.

Support and Acknowledgments: This study was supported by Jazz Pharmaceuticals. Under the direction of the authors, Peloton Advantage, LLC (an OPEN Health company) employees Emily Bruggeman, PhD, and Shawn Jaramillo, PharmD, provided medical writing support and Christopher Jaworski provided editorial support, which were funded by Jazz Pharmaceuticals.

Disclosures: DT Plante is a consultant and advisory board member for Jazz Pharmaceuticals. He has also served as a consultant/advisory board member for Alkermes, Harmony Biosciences, and Takeda and a consultant for Aditum Bio, LLC and Teva Pharmaceuticals (Australia). **DA Nichols, JK Alexander,** and **DS Fuller** are full-time employees of Jazz Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. **TL Steininger** is a former full-time employee and current contract worker for Jazz Pharmaceuticals who previously has received shares of Jazz Pharmaceuticals, plc. **C Ruoff** has served as an advisory board member for Jazz Pharmaceuticals, Eisai, Alkermes, and Takeda and has received grant funding from Jazz Pharmaceuticals.

Scan this code to access this poster online. This code is not for promotional purposes.

Presented at SLEEP 2024, the 38th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS); June 1–5, 2024; Houston, TX, USA